AstraZeneca: Biliary Tract Neoplasms trials

The registry lists 18 Biliary Tract Neoplasms studies with AstraZeneca as lead sponsor. 4 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 5Phase 3 6No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)RecruitingNCT07221253Phase 3
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingNCT06467357Phase 3
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2RecruitingNCT06219941Phase 2
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingNCT05489211Phase 2
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active, not recruitingNCT03875235Phase 3Results posted
• Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 StudyTerminatedNCT01949870Phase 1Results posted
• A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC PatientsCompletedNCT07101874
• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
• Study for AZD4360 in Participants With Advanced Solid TumoursActive, not recruitingNCT06921928Phase 1/2
• Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)Active, not recruitingNCT06109779Phase 3
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3
• Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05835778
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
• Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Active, not recruitingNCT05771480Phase 3
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)CompletedNCT04068168
• A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1
• A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursCompletedNCT01938612Phase 1